Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma

Amy Krambeck, Haidong Dong, R. Houston Thompson, Susan M. Kuntz, Christine M. Lohse, Bradley C. Leibovich, Michael L. Blute, Thomas J. Sebo, John C. Cheville, Alexander S. Parker, Eugene D. Kwon

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Purpose: Clear cell renal cell carcinoma (ccRCC) is an immunogenic tumor that can progress in the presence of an intact host immune system. We previously reported that survivin and B7-H1 are independently associated with disease progression and death when expressed by ccRCC tumors. Herein, we examine the clinical effect of ccRCC combined expression of both survivin and B7-H1. Experimental Design: Specimens from 298 patients who underwent nephrectomy for ccRCC between 1990 and 1994 were immunohistochemically stained for survivin and B7-H1. Cancer-specific survival was estimated using the Kaplan-Meier method. Associations of both markers with ccRCC death were assessed using Cox proportional hazards regression models. Results: At last follow-up, 94 patients died from ccRCC. Among the living patients, the median follow-up was 11.2 years (range, 0-15 years). There were 177 (59.4%) survivin Low/B7-H1 -, 51 (17.1%) survivin Hi/B7-H1-, 29 (9.7%) survivin Low/B7-H1+, and 41 (13.8%) survivin Hi/B7-H1+ tumors. The 5-year cancer-specific survival rates for patients within each group were 89.3%, 59.7%, 70.0%, and 16.2%, respectively. Combined survivin Hi/B7-H1+ expression was associated with ccRCC death univariately (risk ratio, 12.82; 95% confidence interval, 7.50-21.92; P < 0.001) and in multivariate analysis (risk ratio, 2.81; 95% confidence interval, 1.56-5.04; P < 0.001). Survivin Hi/B7-H1+ tumors exhibited increased levels of infiltrating mononuclear cells and survivin-specific T cells compared with survivin Low/B7-H1-tumors. Conclusion: Patients with survivin Hi/B7-H1+ ccRCC tumors are at increased risk of ccRCC death. Survivin Hi/B7-H1+ tumors also harbor increased amounts of infiltrating mononuclear cells and survivin-specific T cells relative to survivin Low/B7-H1-tumors. Taken together, dual expression of survivin and B7-H1 can be used to predict ccRCC tumor aggressiveness.

Original languageEnglish (US)
Pages (from-to)1749-1756
Number of pages8
JournalClinical Cancer Research
Volume13
Issue number6
DOIs
StatePublished - Mar 15 2007
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Survival
Neoplasms
Therapeutics
Cell Death
Odds Ratio
Confidence Intervals
T-Lymphocytes
Nephrectomy
Proportional Hazards Models
Disease Progression
Immune System
Research Design
Multivariate Analysis
Survival Rate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. / Krambeck, Amy; Dong, Haidong; Thompson, R. Houston; Kuntz, Susan M.; Lohse, Christine M.; Leibovich, Bradley C.; Blute, Michael L.; Sebo, Thomas J.; Cheville, John C.; Parker, Alexander S.; Kwon, Eugene D.

In: Clinical Cancer Research, Vol. 13, No. 6, 15.03.2007, p. 1749-1756.

Research output: Contribution to journalArticle

Krambeck, A, Dong, H, Thompson, RH, Kuntz, SM, Lohse, CM, Leibovich, BC, Blute, ML, Sebo, TJ, Cheville, JC, Parker, AS & Kwon, ED 2007, 'Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma', Clinical Cancer Research, vol. 13, no. 6, pp. 1749-1756. https://doi.org/10.1158/1078-0432.CCR-06-2129
Krambeck, Amy ; Dong, Haidong ; Thompson, R. Houston ; Kuntz, Susan M. ; Lohse, Christine M. ; Leibovich, Bradley C. ; Blute, Michael L. ; Sebo, Thomas J. ; Cheville, John C. ; Parker, Alexander S. ; Kwon, Eugene D. / Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 6. pp. 1749-1756.
@article{802f1d9325524f55a2ad764111f7e9a5,
title = "Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma",
abstract = "Purpose: Clear cell renal cell carcinoma (ccRCC) is an immunogenic tumor that can progress in the presence of an intact host immune system. We previously reported that survivin and B7-H1 are independently associated with disease progression and death when expressed by ccRCC tumors. Herein, we examine the clinical effect of ccRCC combined expression of both survivin and B7-H1. Experimental Design: Specimens from 298 patients who underwent nephrectomy for ccRCC between 1990 and 1994 were immunohistochemically stained for survivin and B7-H1. Cancer-specific survival was estimated using the Kaplan-Meier method. Associations of both markers with ccRCC death were assessed using Cox proportional hazards regression models. Results: At last follow-up, 94 patients died from ccRCC. Among the living patients, the median follow-up was 11.2 years (range, 0-15 years). There were 177 (59.4{\%}) survivin Low/B7-H1 -, 51 (17.1{\%}) survivin Hi/B7-H1-, 29 (9.7{\%}) survivin Low/B7-H1+, and 41 (13.8{\%}) survivin Hi/B7-H1+ tumors. The 5-year cancer-specific survival rates for patients within each group were 89.3{\%}, 59.7{\%}, 70.0{\%}, and 16.2{\%}, respectively. Combined survivin Hi/B7-H1+ expression was associated with ccRCC death univariately (risk ratio, 12.82; 95{\%} confidence interval, 7.50-21.92; P < 0.001) and in multivariate analysis (risk ratio, 2.81; 95{\%} confidence interval, 1.56-5.04; P < 0.001). Survivin Hi/B7-H1+ tumors exhibited increased levels of infiltrating mononuclear cells and survivin-specific T cells compared with survivin Low/B7-H1-tumors. Conclusion: Patients with survivin Hi/B7-H1+ ccRCC tumors are at increased risk of ccRCC death. Survivin Hi/B7-H1+ tumors also harbor increased amounts of infiltrating mononuclear cells and survivin-specific T cells relative to survivin Low/B7-H1-tumors. Taken together, dual expression of survivin and B7-H1 can be used to predict ccRCC tumor aggressiveness.",
author = "Amy Krambeck and Haidong Dong and Thompson, {R. Houston} and Kuntz, {Susan M.} and Lohse, {Christine M.} and Leibovich, {Bradley C.} and Blute, {Michael L.} and Sebo, {Thomas J.} and Cheville, {John C.} and Parker, {Alexander S.} and Kwon, {Eugene D.}",
year = "2007",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-06-2129",
language = "English (US)",
volume = "13",
pages = "1749--1756",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Survivin and B7-H1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma

AU - Krambeck, Amy

AU - Dong, Haidong

AU - Thompson, R. Houston

AU - Kuntz, Susan M.

AU - Lohse, Christine M.

AU - Leibovich, Bradley C.

AU - Blute, Michael L.

AU - Sebo, Thomas J.

AU - Cheville, John C.

AU - Parker, Alexander S.

AU - Kwon, Eugene D.

PY - 2007/3/15

Y1 - 2007/3/15

N2 - Purpose: Clear cell renal cell carcinoma (ccRCC) is an immunogenic tumor that can progress in the presence of an intact host immune system. We previously reported that survivin and B7-H1 are independently associated with disease progression and death when expressed by ccRCC tumors. Herein, we examine the clinical effect of ccRCC combined expression of both survivin and B7-H1. Experimental Design: Specimens from 298 patients who underwent nephrectomy for ccRCC between 1990 and 1994 were immunohistochemically stained for survivin and B7-H1. Cancer-specific survival was estimated using the Kaplan-Meier method. Associations of both markers with ccRCC death were assessed using Cox proportional hazards regression models. Results: At last follow-up, 94 patients died from ccRCC. Among the living patients, the median follow-up was 11.2 years (range, 0-15 years). There were 177 (59.4%) survivin Low/B7-H1 -, 51 (17.1%) survivin Hi/B7-H1-, 29 (9.7%) survivin Low/B7-H1+, and 41 (13.8%) survivin Hi/B7-H1+ tumors. The 5-year cancer-specific survival rates for patients within each group were 89.3%, 59.7%, 70.0%, and 16.2%, respectively. Combined survivin Hi/B7-H1+ expression was associated with ccRCC death univariately (risk ratio, 12.82; 95% confidence interval, 7.50-21.92; P < 0.001) and in multivariate analysis (risk ratio, 2.81; 95% confidence interval, 1.56-5.04; P < 0.001). Survivin Hi/B7-H1+ tumors exhibited increased levels of infiltrating mononuclear cells and survivin-specific T cells compared with survivin Low/B7-H1-tumors. Conclusion: Patients with survivin Hi/B7-H1+ ccRCC tumors are at increased risk of ccRCC death. Survivin Hi/B7-H1+ tumors also harbor increased amounts of infiltrating mononuclear cells and survivin-specific T cells relative to survivin Low/B7-H1-tumors. Taken together, dual expression of survivin and B7-H1 can be used to predict ccRCC tumor aggressiveness.

AB - Purpose: Clear cell renal cell carcinoma (ccRCC) is an immunogenic tumor that can progress in the presence of an intact host immune system. We previously reported that survivin and B7-H1 are independently associated with disease progression and death when expressed by ccRCC tumors. Herein, we examine the clinical effect of ccRCC combined expression of both survivin and B7-H1. Experimental Design: Specimens from 298 patients who underwent nephrectomy for ccRCC between 1990 and 1994 were immunohistochemically stained for survivin and B7-H1. Cancer-specific survival was estimated using the Kaplan-Meier method. Associations of both markers with ccRCC death were assessed using Cox proportional hazards regression models. Results: At last follow-up, 94 patients died from ccRCC. Among the living patients, the median follow-up was 11.2 years (range, 0-15 years). There were 177 (59.4%) survivin Low/B7-H1 -, 51 (17.1%) survivin Hi/B7-H1-, 29 (9.7%) survivin Low/B7-H1+, and 41 (13.8%) survivin Hi/B7-H1+ tumors. The 5-year cancer-specific survival rates for patients within each group were 89.3%, 59.7%, 70.0%, and 16.2%, respectively. Combined survivin Hi/B7-H1+ expression was associated with ccRCC death univariately (risk ratio, 12.82; 95% confidence interval, 7.50-21.92; P < 0.001) and in multivariate analysis (risk ratio, 2.81; 95% confidence interval, 1.56-5.04; P < 0.001). Survivin Hi/B7-H1+ tumors exhibited increased levels of infiltrating mononuclear cells and survivin-specific T cells compared with survivin Low/B7-H1-tumors. Conclusion: Patients with survivin Hi/B7-H1+ ccRCC tumors are at increased risk of ccRCC death. Survivin Hi/B7-H1+ tumors also harbor increased amounts of infiltrating mononuclear cells and survivin-specific T cells relative to survivin Low/B7-H1-tumors. Taken together, dual expression of survivin and B7-H1 can be used to predict ccRCC tumor aggressiveness.

UR - http://www.scopus.com/inward/record.url?scp=34250209885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250209885&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-2129

DO - 10.1158/1078-0432.CCR-06-2129

M3 - Article

VL - 13

SP - 1749

EP - 1756

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -